Agent-Directed Tracing of Multi-Scale Drug Disposition Events within Normal and Diseased In Silico Livers

Agent-Directed Tracing of Multi-Scale Drug Disposition Events within Normal and Diseased In Silico Livers

Sean H. J. Kim (University of California, San Francisco, USA), Sunwoo Park (University of California, San Francisco, USA), Glen E. P. Ropella (Tempus Dictum, Inc., USA) and C. Anthony Hunt (University of California, San Francisco, USA)
Copyright: © 2010 |Pages: 19
DOI: 10.4018/jats.2010070101
OnDemand PDF Download:
No Current Special Offers


Cirrhosis, a chronic liver disease, alters hepatic drug disposition; however, little is known about micro-mechanisms underpinning disease progression and how they contribute to changes in liver disposition properties. In this article, the authors present multilevel, agent-based and agent-directed In Silico Livers (ISLs) to probe plausible micro-mechanistic details for a cationic drug, diltiazem, in two different types of cirrhotic rat livers. Starting with ISLs that validated against diltiazem disposition data from normal livers, the authors systematically transformed ISL characteristics to achieve validation against perfusion outflow profiles from the two types of diseased livers. In this regard, the authors developed and implemented multilevel methods to trace each object representing diltiazem during simulated perfusion experiments. This enabled gaining heretofore-unavailable insight into plausible micro-mechanistic details from diltiazem’s perspective in normal and diseased livers. The authors posit that the presented ISL micro-mechanistic details may have disease caused counterparts during disposition.
Article Preview


Cirrhosis includes chronic, advanced fibrosis (scarring) of liver, a major site of drug metabolism and clearance. It results from the perpetuation of the normal wound healing response and subsequent distortion of hepatic histoarchitecture. The disease complicates drug therapy management because it alters hepatic drug disposition, which, in turn, alters pharmacokinetic (PK) and/or pharmacodynamic characteristics. The nature of that alteration is dependent on the nature and the extent of disease. With some exceptions (Hung et al., 2002), little is known about exactly how the cirrhotic changes affect hepatic drug disposition. Improved, mechanistic insight is needed to enable rational drug therapy based on clinical measures of both type and extent of liver disease.

We have used a new strategy to achieve improved insight. It involves developing and experimenting on multi-scale In Silico Livers (ISLs) (Park, Ropella, Kim, Roberts, & Hunt, 2009). Key ISL and support components were represented as independent, interacting agents. In silico experiments were conducted using an automated, high-performance software environment capable of parallel computation. We started with ISLs that validated for drug and sucrose disposition profiles of normal rat livers in situ (Yan, Ropella, Park, Roberts, & Hunt, 2008). The models were then subjected to cycles of experimentation and iterative refinement to achieve simulated drug disposition profiles that were acceptably similar to those from two different types of diseased livers (Hung et al., 2002). The diseased ISLs were created independently: for each type, an increasing number of normal ISL characteristics were altered systematically until simulated drug disposition profiles were experimentally indistinguishable from the referent profiles.

Having achieved a degree of validation, we posit that the causative, mechanistic details occurring during ISL execution may have hepatic counterparts during disposition, as diagrammed in Figure 1. Differences in micro-mechanistic details between the normal and the two “diseased” ISLs are hypotheses about corresponding differences between the normal and diseased livers, and about differences between diseased livers. Achieving a degree of profile similarity is evidence supporting those hypotheses. The differences in dynamic, multilevel details during execution of the two diseased ISLs provide a plausible, physiologically based explanation of the disease-caused differences in hepatic drug disposition. With additional rounds of refinement and validation, future ISLs are expected to provide increasingly useful scientific predictions and deeper insight into mechanistic details of disease progression and its role in hepatic PK.

Figure 1.

Relationships between perfused rat liver models and In Silico Livers (ISLs). (A) Perfused rat livers in their experimental context are the referent systems. During experiments, liver components interact with transiting drug molecules causing changes in the compound’s outflow profile. Systemic behaviors at all levels are reflected in the collected data. (B) ISL components are designed, coded, verified, and assembled based on mechanism and component descriptions that are physiologically based. Concretizable mapping 1 is intended to exist from ISL components and interactions to hepatic physiological and micro-anatomic details. System dynamics during execution (mapping 2) are intended to abstractly represent plausible corresponding dynamics occurring within the liver during disposition. Measures of dynamics provide time series data that are intended to mimic counterpart measures of wet-laboratory perfusion experiments. Achieving measurable similarities makes mapping 3 quantitative. (C) Diseased counterparts to normal ISLs can be achieved by iteratively altering a subset of normal parameter values, mechanisms, and events into diseased counterparts that validate. Conceptual mappings are offered to relate differences in parameter values (normal to diseased) to measures of histopathology.


Complete Article List

Search this Journal:
Open Access Articles: Forthcoming
Volume 9: 1 Issue (2017)
Volume 8: 1 Issue (2016)
Volume 7: 3 Issues (2015)
Volume 6: 4 Issues (2014)
Volume 5: 4 Issues (2013)
Volume 4: 4 Issues (2012)
Volume 3: 4 Issues (2011)
Volume 2: 4 Issues (2010)
Volume 1: 4 Issues (2009)
View Complete Journal Contents Listing